BackNewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV Other Current Liabilities

Track NewAmsterdam Pharma Company NV's other current liabilities ($65M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$64.73M
↑ 112.98% YoYΔ $34.34M vs prior year quarter

Peer trimmed avg / median

Loading

NewAmsterdam Pharma Company NV Other Current Liabilities History

Loading

NewAmsterdam Pharma Company NV vs. peers: Other Current Liabilities Comparison

Loading

NewAmsterdam Pharma Company NV Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NewAmsterdam Pharma Company NV (NAMS) FAQ

NewAmsterdam Pharma Company NV (NAMS) currently reports a other current liabilities of $65M as of June 2026. That compares with $30M in the prior-year period — up 113.0% year over year. Use the charts on this page to explore NewAmsterdam Pharma Company NV's other current liabilities history and peer comparisons.

NewAmsterdam Pharma Company NV's other current liabilities increased from $30M to $65M — a 113.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NewAmsterdam Pharma Company NV reported $65M in other current liabilities as of June 2026. That compares with $30M in the prior-year period — up 113.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $65M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV, and consider following NAMS for alerts when major investors trade the stock.